Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib - Astellas Pharma/Pfizer

Drug Profile

Celecoxib - Astellas Pharma/Pfizer

Alternative Names: Celebra; Celebrex; Celecox; Niflam; Onsenal; SC-58635; YM-177

Latest Information Update: 20 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Dana-Farber Cancer Institute; Department of Veterans Affairs; Imperial College of Science, Technology and Medicine; Linkoping University Hospital; Pfizer; Swedish Lung Cancer Study Group; University Clinic Golnik; University of Connecticut; Zydus Cadila
  • Class Antimigraines; Antineoplastics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute pain; Ankylosing spondylitis; Back pain; Cervicobrachial syndrome; Dental pain; Dysmenorrhoea; Familial adenomatous polyposis; Juvenile rheumatoid arthritis; Osteoarthritis; Pain; Periarthritis; Postoperative pain; Rheumatic disorders; Rheumatoid arthritis; Tendinitis; Tenosynovitis
  • Phase III Breast cancer; Non-small cell lung cancer
  • Phase II Small cell lung cancer; Stomatitis
  • Discontinued Alzheimer's disease; Bladder cancer; Gouty arthritis; Prostate cancer

Most Recent Events

  • 24 Apr 2019 Pfizer completes a phase II trial in Small cell lung cancer (Late-stage disease, First-line therapy) in Slovenia (PO) (EudraCT 2012-001877)
  • 12 Apr 2019 Pfizer terminates the phase III REACT trial in Breast cancer (Second-line therapy or greater) in United Kingdom as the trial already reached its objectives, and no further data collection was needed (PO) (ISRCTN48254013)
  • 01 Mar 2019 Pfizer completes the phase III REACT trial in Breast cancer (Second-line therapy or greater) in United Kingdom (PO) (ISRCTN48254013) (NCT02429427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top